Retraction: A Novel Copper Chelate Modulates Tumor Associated Macrophages to Promote Anti-Tumor Response of T Cells (PLoS ONE (2009) 4: 9 (e7048) DOI: 10.1371/journal.pone.0007048);A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Chatterjee, Shilpak ^a   Mookerjee, Ananda ^b   Basu, Jayati Mookerjee ^b   Chakraborty, Paramita ^a   Ganguly, Avishek ^a   Adhikary, Arghya ^c   Mukhopadhyay, Debanjan ^d   Ganguli, Sudipta ^d   Banerjee, Rajdeep ^e   Ashraf, Mohammad ^a   Biswas, Jaydip ^a   Das, Pradeep K ^e   Sa, Gourisankar ^c   Chatterjee, Mitali ^d   Das, Tanya ^c   Choudhuri, Soumitra Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b CHU PURPAN   (France)

^c BOSE INSTITUTE   (India)

^d INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^e RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; COPPER N (2 HYDROXY ACETOPHENONE)GLYCINATE; CUPRIC ION; GAMMA INTERFERON; GLYCINATE COPPER; INTERLEUKIN 10; INTERLEUKIN 12; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CHELATING AGENT; COPPER; COPPER (N 2 HYDROXYACETOPHENONE)GLYCINATE; COPPER (N-2-HYDROXYACETOPHENONE)GLYCINATE; DRUG DERIVATIVE; GLYCINE; INTERLEUKIN 2 RECEPTOR ALPHA; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CASE REPORT; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHELATION THERAPY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; ANIMAL; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CHEMISTRY; DRUG RESISTANCE; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; METABOLISM; METASTASIS; METHODOLOGY; MONONUCLEAR CELL; MOUSE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHELATING AGENTS; COPPER; DRUG RESISTANCE, NEOPLASM; GLYCINE; IMMUNE SYSTEM; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; TH1 CELLS;

EID: 70349488306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0286555     Document Type: Erratum

References (46)

1. Van der Bruggen P, Traversari C, Chomoez P, Lurquin C, De plean E, et al. (1991) A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254: 1643-1647.
2. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, et al. (1998) The central role of CD4+ T cells in the antitumor immune response. J Exp Med 188: 2357-2368.
3. Zou W (2005) Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.
4. Whiteside TL (2005) Immunology of head and neck cancer. Cancer Metastasis Rev 24: 95-105.
5. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555.
6. Bronte V, Serafini P, Apolloni E, Zanovello P (2001) Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 24: 431-446.
7. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, et al. (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629.
8. Sunderkötter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, Sorg C (1991) Macrophage-derived angiogenesis factors. Pharmacol Ther 51: 195-216.
9. Bicknell R, Harris AL (1991) Novel growth regulatory factors and tumor angiogenesis. Eur J Cancer 27: 781-785.
10. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukocyte Biol 64: 275-290.
11. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, et al. (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)FoxP3(+) T cells. Gastroenterology 135: 234-243.
12. Watkins SK, Egilmez NK, Suttles J, Stout RD (2007) IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 178: 1357-1362.
13. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, et al. (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177: 1199-1204.
14. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, et al. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230.
15. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, et al. (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
16. Wall L, Burke F, Barton C, Smyth J, Balkwill F (2003) IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 9: 2487-96.
17. Majumder S, Chatterjee S, Pal S, Biswas J, Efferth T, et al. (2009) The role of copper in drug-resistant murine and human tumors. Biometals 22: 377-384.
18. Percival SS (1998) Copper and immunity. Am J Clin Nutr 67: S1064-S1068.
19. Leary Sc, Winge DR (2007) The Janus face of copper: its expanding role in biology and the pathophysiology of disease. EMBO reports 8: 224-227.
20. Majumder S, Panda GS, Choudhuri SK (2003) Synthesis, characterization and biological properties of a novel copper complex. Eur J Med Chem 38: 893-898.
21. Mookerjee A, Basu JM, Dutta P, Majumder J, Bhattacharya S, et al. (2006) Overcoming drug-resistant in cancer by a newly developed copper chelate through host protective cytokine mediated apoptosis. Clin Cancer Res 12: 4339-4349.
22. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, et al. (Feb 27, 2009) Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer.
23. + T cells secreting interleukin 10 and transforming growth factor β1 mediated suppression in the tumor microenvironment. Clin Cancer Res 13: 4345-4354.
24. Mills KH (2004) Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4: 841-855.
25. Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2000) The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 1: 469-474.
26. + effector and memory T cell generation. Nat Immunol 4: 835-842.
27. + T cells. Immunol Res 36: 275-282.
28. Lu B, Zagouras P, Fischer JE, Lu J, Li B, et al. (2004) Kinetic analysis of genomewide gene expression reveals molecule circuitries that control T cell activation and Th1/Th2 differentiation. Proc Natl Acad Sci 101: 3023-3028.
29. Bharhani MS, Borojevic R, Basak S, Ho E, Zhou P, et al. (2006) IL-10 protects mouse intestinal epithelial cells from Fas-induced apoptosis via modulating Fas expression and altering caspase-8 and FLIP expression. Am J Physiol Gastrointest Liver Physiol 291: G820-G829.
30. Stout RD, Suttles J (2004) Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukocyte Biol 76: 509-513.
31. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, et al. (2005) Macrophages sequentially change their functional phenotype in response to changes in micro environmental influences. J Immunol 175: 342-349.
32. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
33. Pollard JW (2004) Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 4: 71-77.
34. Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256: 158-168.
35. Murphy KM, Reiner SL (2002) The lineage decision of helper T cells. Nat Rev Immunol 2: 933-944.
36. Mosmann TR, Sad S (1996) The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146.
37. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146: 3444-3451.
38. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, et al. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1697-1706.
39. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, et al. (1995) IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J Immunol 155: 2240-2247.
40. Hagenbaugh A, Sharma S, Dubinett S, Wei SH, Aranda R, et al. (1997) Altered immune response in IL-10 transgenic mice. J Exp Med 185: 2101-2110.
41. Kusaba H, Ghosh P, Derin R, Buchholz M, Sasaki C, et al. (2005) Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR). J Biol Chem 280: 1037-1043.
42. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK (2002) Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 196: 999-1005.
43. Murata Y, Shimamura T, Hamuro J (2002) The polarization of Th1/Th2 balance is dependent on the intracellular thiol redox status of macrophage due to the distinctive cytokine production. International Immunology 14: 201-212.
44. Choudhuri SK, Chatterjee A (1998) Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis (N-phenyl) hydroxamic acid in vitro. Anticancer Drugs 9: 825-832.
45. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Sen P, et al. (2006) Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 50: 1788-97.
46. Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, et al. (2008) Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother 53: 1080-1093.